Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial

Reuters

2025/09/11

<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial

Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader $(KOL)$ event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566998286"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566998286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566998286?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566998286","market":"nz","top_or_hot":-1,"title":"Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-11 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KAPA","symbol_name":"Kairos Pharma, Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL9njcbp:1","article_id":"2566998286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566998286","pubTimestamp":1757592032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader  event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KAPA":"Kairos Pharma, Ltd.","BK4139":"生物科技"},"translate_title":"Kairos Pharma将举办KOL活动，讨论ENV105在晚期前列腺癌试验中有希望的中期疗效结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial\n    \n\n        Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader $(KOL)$ event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}